Cook Sarah F, Bies Robert R
Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, 445 Kapoor Hall, Buffalo, NY 14214, USA.
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Curr Pharmacol Rep. 2016 Oct;2(5):221-230. doi: 10.1007/s40495-016-0066-x. Epub 2016 Aug 15.
Disease modeling involves the use of mathematical functions to describe quantitatively the time course of disease progression. In order to characterize the natural progression of disease, these models generally incorporate longitudinal data for some biomarker(s) of disease severity or can incorporate more direct measures of disease severity. Disease models are also often linked to pharmacokinetic-pharmacodynamic models so that the influence of drug treatment on disease progression can be quantified and evaluated. Regulatory agencies have embraced disease progression models as powerful tools that can be used to improve drug development productivity. This article provides a brief overview of key concepts in disease progression modeling followed by illustrative examples from models for Alzheimer's disease. Finally, recent novel applications in which disease progression models have been linked to cost-effectiveness analysis and genomic analysis are described.
疾病建模涉及使用数学函数来定量描述疾病进展的时间过程。为了表征疾病的自然进展,这些模型通常纳入一些疾病严重程度生物标志物的纵向数据,或者可以纳入更直接的疾病严重程度测量指标。疾病模型也常常与药代动力学-药效学模型相联系,以便能够量化和评估药物治疗对疾病进展的影响。监管机构已将疾病进展模型视为可用于提高药物开发效率的有力工具。本文简要概述了疾病进展建模中的关键概念,随后给出了阿尔茨海默病模型的示例。最后,描述了疾病进展模型与成本效益分析和基因组分析相联系的最新新颖应用。